Global Health Limited

NSEI:MEDANTA Stock Report

Market Cap: ₹299.1b

Global Health Valuation

Is MEDANTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MEDANTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MEDANTA (₹1113.65) is trading above our estimate of fair value (₹561.17)

Significantly Below Fair Value: MEDANTA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MEDANTA?

Key metric: As MEDANTA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MEDANTA. This is calculated by dividing MEDANTA's market cap by their current earnings.
What is MEDANTA's PE Ratio?
PE Ratio61.3x
Earnings₹4.88b
Market Cap₹299.07b

Price to Earnings Ratio vs Peers

How does MEDANTA's PE Ratio compare to its peers?

The above table shows the PE ratio for MEDANTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average69.8x
NH Narayana Hrudayalaya
33.2x13.6%₹258.4b
KIMS Krishna Institute of Medical Sciences
71.9x24.3%₹238.2b
ASTERDM Aster DM Healthcare
95.2x37.5%₹215.2b
FORTIS Fortis Healthcare
79x26.8%₹517.8b
MEDANTA Global Health
61.3x20.2%₹299.1b

Price-To-Earnings vs Peers: MEDANTA is good value based on its Price-To-Earnings Ratio (61.3x) compared to the peer average (69.8x).

Price to Earnings Ratio vs Industry

How does MEDANTA's PE Ratio compare vs other companies in the IN Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
523696 Fortis Malar Hospitals
2.1xn/aUS$11.76m
542918 Gian Life Care
4.9xn/aUS$2.33m
No more companies available in this PE range
MEDANTA 61.3xIndustry Avg. 41.9xNo. of Companies5PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: MEDANTA is expensive based on its Price-To-Earnings Ratio (61.3x) compared to the Indian Healthcare industry average (41.9x).

Price to Earnings Ratio vs Fair Ratio

What is MEDANTA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MEDANTA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio61.3x
Fair PE Ratio62.9x

Price-To-Earnings vs Fair Ratio: MEDANTA is good value based on its Price-To-Earnings Ratio (61.3x) compared to the estimated Fair Price-To-Earnings Ratio (62.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MEDANTA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,113.65
₹1,184.25
+6.3%
13.3%₹1,440.00₹855.00n/a12
Nov ’25₹1,115.70
₹1,193.36
+7.0%
12.5%₹1,400.00₹895.00n/a11
Oct ’25₹1,000.65
₹1,207.18
+20.6%
12.5%₹1,400.00₹930.00n/a11
Sep ’25₹1,134.70
₹1,233.90
+8.7%
10.4%₹1,390.00₹980.00n/a10
Aug ’25₹1,222.00
₹1,393.00
+14.0%
6.3%₹1,490.00₹1,245.00n/a9
Jul ’25₹1,270.55
₹1,376.10
+8.3%
10.3%₹1,620.00₹1,089.00n/a10
Jun ’25₹1,191.85
₹1,376.10
+15.5%
10.3%₹1,620.00₹1,089.00n/a10
May ’25₹1,445.20
₹1,352.70
-6.4%
9.8%₹1,530.00₹1,089.00n/a10
Apr ’25₹1,331.25
₹1,336.33
+0.4%
9.6%₹1,470.00₹1,089.00n/a9
Mar ’25₹1,298.65
₹1,336.33
+2.9%
9.6%₹1,470.00₹1,089.00n/a9
Feb ’25₹1,198.40
₹992.00
-17.2%
9.4%₹1,120.00₹875.00n/a9
Jan ’25₹951.35
₹958.63
+0.8%
6.9%₹1,050.00₹875.00n/a8
Dec ’24₹970.00
₹958.63
-1.2%
6.9%₹1,050.00₹875.00n/a8
Nov ’24₹799.60
₹790.00
-1.2%
5.7%₹859.00₹735.00₹1,115.708
Oct ’24₹716.05
₹780.14
+9.0%
5.0%₹840.00₹735.00₹1,000.657
Sep ’24₹706.75
₹754.33
+6.7%
3.1%₹780.00₹720.00₹1,134.706
Aug ’24₹679.70
₹687.80
+1.2%
7.9%₹780.00₹620.00₹1,222.005
Jul ’24₹659.25
₹667.50
+1.3%
4.8%₹710.00₹620.00₹1,270.554
Jun ’24₹587.15
₹653.33
+11.3%
3.7%₹675.00₹620.00₹1,191.853
May ’24₹515.95
₹585.00
+13.4%
5.7%₹630.00₹550.00₹1,445.203
Apr ’24₹526.95
₹602.50
+14.3%
4.6%₹630.00₹575.00₹1,331.252
Mar ’24₹509.70
₹602.50
+18.2%
4.6%₹630.00₹575.00₹1,298.652

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Medico Intercontinental

₹592.5m

Trades in pharmaceutical products.

539938

₹59.25

7D

28.6%

1Y

-37.0%

N G Industries

₹547.0m

Provides various healthcare services in India.

530897

₹163.25

7D

-2.7%

1Y

-2.5%

Dr Lalchandani Labs

₹78.0m

Provides diagnostic and related healthcare tests and services in India.

541299

₹18.00

7D

0%

1Y

n/a